NEW YORK, October 10, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Cell Therapeutics, Inc. (NASDAQ: CTIC), PDL BioPharma, Inc. (NASDAQ: PDLI), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Acorda Therapeutics, Inc. (NASDAQ: ACOR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Aegerion Pharmaceuticals, Inc. Research Report
On October 7, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) announced that it has granted stock options to nine new employees to purchase an aggregate of 54,047 shares of common stock under the inducement stock option program, on October 1, 2013. The Company informed that each stock option has an exercise price per share of $90.25; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over three years thereafter; has a ten year term and is subject to the terms and conditions of the Company's Inducement Award Stock Option Plan. Further, Aegerion reported that the Compensation Committee of its Board of Directors has approved the reservation of one million shares of common stock to be used exclusively for the grant of non-qualified stock options to individuals who were not previously an employee or non-employee director of Aegerion (or following a bona fide period of non-employment), as an inducement new hire stock option award material to an individual's entry into employment. The Full Research Report on Aegerion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/a3f6_AEGR]
Cell Therapeutics, Inc. Research Report
On October 7, 2013, Cell Therapeutics, Inc. (CTI) announced that it has reached an agreement with the US Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the planned pivotal Phase 3 clinical trial, the PERSIST-2 trial, which evaluates pacritinib compared to best available therapy in patients with myelofibrosis whose platelet counts are < 100,000/uL. The SPA is a written agreement between CTI and FDA regarding the design, endpoints, and planned statistical analysis approach of the trial to be used in support of a potential New Drug Application (NDA) submission. The Company expects to initiate the PERSIST-2 clinical trial in Q4 2013.Commenting on the agreement, James A. Bianco, M.D., CTI's President and CEO stated, "The FDA worked closely with us to achieve SPA agreement during first cycle review of the PERSIST-2 trial protocol for pacritinib. As a result of the SPA, which established agreement on trial design to support regulatory approval, we expect that we will be able to initiate this pivotal Phase 3 clinical trial of pacritinib by the end of the year." The Full Research Report on Cell Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/f9df_CTIC]
PDL BioPharma, Inc. Research Report
On October 2, 2013, PDL BioPharma, Inc. (PDL) announced that it has closed a financing transaction with LENSAR, Inc. (LENSAR), under which PDL will provide LENSAR with up to $60 million of debt financing, as part of an $87 million total financing for LENSAR. In exchange, PDL has received a security interest in all of LENSAR's assets and will receive interest on the principal amount outstanding. "With this financial commitment from PDL, LENSAR is now fully positioned to address the multi-billion dollar laser addressable cataract surgery market with what we believe to be a superior product," said John P. McLaughlin, President and CEO of PDL. The Full Research Report on PDL BioPharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/066b_PDLI]
Halozyme Therapeutics, Inc. Research Report
On September 30, 2013, Halozyme Therapeutics, Inc. (Halozyme) announced mature patient progression free survival (PFS) and ongoing overall survival (OS) data from its Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with gemcitabine for the treatment of patients with stage IV metastatic pancreatic cancer. The data from both PFS and OS indicates a potential clinical benefit of using PEGPH20 with gemcitabine in patients with high levels of tumor associated hyaluronan (HA). Sunil R. Hingorani M.D., Ph.D., Associate Member of the Clinical and Public Health Divisions at Fred Hutchinson Cancer Research Center and lead investigator for the study said, "PEGPH20 has been shown in animal studies to deplete HA from tumors and improve perfusion and drug delivery to the tumor bed. The data from this trial suggest that similar processes may be occurring in patients as well and that patients with high levels of HA may derive the most treatment benefit from PEGPH20 combination therapy." The Full Research Report on Halozyme Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/ea1b_HALO]
Acorda Therapeutics, Inc. Research Report
On October 7, 2013, Acorda Therapeutics, Inc. (Acorda) announced the appointment of Michael Rogers as the Company's CFO, effective October 7, 2013. Rogers will assume the responsibility for Acorda's Finance and Investor Relations departments. The Company also reported that David Lawrence, M.B.A.,who previously served as the Company's CFO, has been appointed as Chief of Business Operations (CBO) and will be responsible for Technical Operations/Manufacturing, Project Management, Information Technology, and Facilities Management. The Full Research Report on Acorda Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d67c_ACOR]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner